Friday, August 1, 2025

Psyched Wellness Sees Professor David Nutt Move From Advisory Role To Directorship

It appears that Professor David Nutt has a desire to become more involved with that of Psyched Wellness (CSE: PSYC). Currently the chair of the Scientific Advisory Board for Compass Pathways (NASDAQ: CMPS), Nutt has elected to step up from his role as an advisor to Psyched Wellness to that of a directorship.

Nutt is well versed in the area of psychopharmacology, which is the study of the effects of drugs on the brain. In layman terms, his focus is on how and why addictions can occur, as well as how treatments in both psychiatry and neurology work. Presently, he works as a psychiatrist as the Edmond J. Safra Chair of Neuropsychopharmacology at Imperial College London, within the Division of Brain Sciences.

Speaking specifically to his work, Nutt is well respected within the field, with his research having lead to over 500 original research papers. Furthermore, a comparable number of reviews and book chapters have been written by Nutt, along with eight government reports on drugs and 35 books. Not all of his writing has been directed to the medical community specifically, with one book, Drugs: Without the Hot Air, being written for consumption by the general public.

Past roles held by Nutt are rather impressive as well, with him having served as President of four separate medical councils: The European Brain Council, the European College of Neuropsychopharmacology, the British Association of Pharmacology, and the British Neuroscience Association. He’s also the founding chair of Drug Science, while holding visiting professorships at multiple universities.

“As a recent pioneer in the field of psychedelic medicine I have long been fascinated by the centuries-old use of Amanita Muscaria. When Psyched Wellness offered me the chance to bring this novel psychedelic mushroom into modern science and medicine, I jumped at it!”

Professor David Nutt

Psyched Wellness last traded at $0.13 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why Gold’s Bull Run May Just Be Getting Started! | Peter Grandich

Tariffs Spark New Race for Critical Metals | Rob McEwen

Antimony Resources: The Bald Hill Project

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

Psyched Wellness Files Patent Application For Proprietary AME-1 Extraction Process

Psyched Wellness (CSE: PSYC) has begun the process of protecting its intellectual property. The firm...

Wednesday, March 17, 2021, 07:32:20 AM

Psyched Wellness Signs Two Year Supply Agreement For Amanita Muscaria

Psyched Wellness (CSE: PSYC) this morning had a brief announcement. Within, the company revealed that...

Tuesday, May 4, 2021, 08:36:07 AM

Psyched Wellness Moves To Next Stage Of Pre-Clinical Trials With Mushroom Extract

Psyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the...

Thursday, October 7, 2021, 08:21:06 AM

Psyched Wellness Completes First Step In Study Identifying Potential Of Muscimol

Psyched Wellness (CSE: PSYC) has completed the first step in identifying the medicinal potential of...

Thursday, January 14, 2021, 06:58:13 AM

Psyched Wellness Latest Firm To Conduct Bought Deal Financing

Psyched Wellness (CSE: PSYC) is the latest psychedelics-focused firm to announce a bought deal financing,...

Thursday, January 21, 2021, 07:53:05 PM